Cargando…

Cationic polyamines inhibit anthrax lethal factor protease

BACKGROUND: Anthrax is a human disease that results from infection by the bacteria, Bacillus anthracis and has recently been used as a bioterrorist agent. Historically, this disease was associated with Bacillus spore exposure from wool or animal carcasses. While current vaccine approaches (targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Mark Evan, Cregar, Lynne, Nguyen, Dominique, Simo, Ondrej, O'Malley, Sean, Humphreys, Tom
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513218/
https://www.ncbi.nlm.nih.gov/pubmed/16762077
http://dx.doi.org/10.1186/1471-2210-6-8
_version_ 1782128460133564416
author Goldman, Mark Evan
Cregar, Lynne
Nguyen, Dominique
Simo, Ondrej
O'Malley, Sean
Humphreys, Tom
author_facet Goldman, Mark Evan
Cregar, Lynne
Nguyen, Dominique
Simo, Ondrej
O'Malley, Sean
Humphreys, Tom
author_sort Goldman, Mark Evan
collection PubMed
description BACKGROUND: Anthrax is a human disease that results from infection by the bacteria, Bacillus anthracis and has recently been used as a bioterrorist agent. Historically, this disease was associated with Bacillus spore exposure from wool or animal carcasses. While current vaccine approaches (targeted against the protective antigen) are effective for prophylaxis, multiple doses must be injected. Common antibiotics that block the germination process are effective but must be administered early in the infection cycle. In addition, new therapeutics are needed to specifically target the proteolytic activity of lethal factor (LF) associated with this bacterial infection. RESULTS: Using a fluorescence-based assay to identify and characterize inhibitors of anthrax lethal factor protease activity, we identified several chemically-distinct classes of inhibitory molecules including polyamines, aminoglycosides and cationic peptides. In these studies, spermine was demonstrated for the first time to inhibit anthrax LF with a K(i )value of 0.9 ± 0.09 μM (mean ± SEM; n = 3). Additional linear polyamines were also active as LF inhibitors with lower potencies. CONCLUSION: Based upon the studies reported herein, we chose linear polyamines related to spermine as potential lead optimization candidates and additional testing in cell-based models where cell penetration could be studied. During our screening process, we reproducibly demonstrated that the potencies of certain compounds, including neomycin but not neamine or spermine, were different depending upon the presence or absence of nucleic acids. Differential sensitivity to the presence/absence of nucleic acids may be an additional point to consider when comparing various classes of active compounds for lead optimization.
format Text
id pubmed-1513218
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15132182006-07-20 Cationic polyamines inhibit anthrax lethal factor protease Goldman, Mark Evan Cregar, Lynne Nguyen, Dominique Simo, Ondrej O'Malley, Sean Humphreys, Tom BMC Pharmacol Research Article BACKGROUND: Anthrax is a human disease that results from infection by the bacteria, Bacillus anthracis and has recently been used as a bioterrorist agent. Historically, this disease was associated with Bacillus spore exposure from wool or animal carcasses. While current vaccine approaches (targeted against the protective antigen) are effective for prophylaxis, multiple doses must be injected. Common antibiotics that block the germination process are effective but must be administered early in the infection cycle. In addition, new therapeutics are needed to specifically target the proteolytic activity of lethal factor (LF) associated with this bacterial infection. RESULTS: Using a fluorescence-based assay to identify and characterize inhibitors of anthrax lethal factor protease activity, we identified several chemically-distinct classes of inhibitory molecules including polyamines, aminoglycosides and cationic peptides. In these studies, spermine was demonstrated for the first time to inhibit anthrax LF with a K(i )value of 0.9 ± 0.09 μM (mean ± SEM; n = 3). Additional linear polyamines were also active as LF inhibitors with lower potencies. CONCLUSION: Based upon the studies reported herein, we chose linear polyamines related to spermine as potential lead optimization candidates and additional testing in cell-based models where cell penetration could be studied. During our screening process, we reproducibly demonstrated that the potencies of certain compounds, including neomycin but not neamine or spermine, were different depending upon the presence or absence of nucleic acids. Differential sensitivity to the presence/absence of nucleic acids may be an additional point to consider when comparing various classes of active compounds for lead optimization. BioMed Central 2006-06-08 /pmc/articles/PMC1513218/ /pubmed/16762077 http://dx.doi.org/10.1186/1471-2210-6-8 Text en Copyright © 2006 Goldman et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Goldman, Mark Evan
Cregar, Lynne
Nguyen, Dominique
Simo, Ondrej
O'Malley, Sean
Humphreys, Tom
Cationic polyamines inhibit anthrax lethal factor protease
title Cationic polyamines inhibit anthrax lethal factor protease
title_full Cationic polyamines inhibit anthrax lethal factor protease
title_fullStr Cationic polyamines inhibit anthrax lethal factor protease
title_full_unstemmed Cationic polyamines inhibit anthrax lethal factor protease
title_short Cationic polyamines inhibit anthrax lethal factor protease
title_sort cationic polyamines inhibit anthrax lethal factor protease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513218/
https://www.ncbi.nlm.nih.gov/pubmed/16762077
http://dx.doi.org/10.1186/1471-2210-6-8
work_keys_str_mv AT goldmanmarkevan cationicpolyaminesinhibitanthraxlethalfactorprotease
AT cregarlynne cationicpolyaminesinhibitanthraxlethalfactorprotease
AT nguyendominique cationicpolyaminesinhibitanthraxlethalfactorprotease
AT simoondrej cationicpolyaminesinhibitanthraxlethalfactorprotease
AT omalleysean cationicpolyaminesinhibitanthraxlethalfactorprotease
AT humphreystom cationicpolyaminesinhibitanthraxlethalfactorprotease